Radiotheranostics Market Report 2026

Radiotheranostics Market Overview

• Radiotheranostics market size has reached to $10.05 billion in 2025 • Expected to grow to $19.24 billion in 2030 at a compound annual growth rate (CAGR) of 13.9% • Growth Driver: Rising Prevalence Of Cancer To Drive Market Growth • Market Trend: Product Innovations Transforming The Radiotheranostics Market • North America was the largest region in 2025.

What Is Covered Under Radiotheranostics Market?

Radiotheranostics refers to diagnoses and treatments that utilize imaging methods with radioactive substances to pinpoint specific targets in the body. It is used to administer targeted radiation therapy to defined locations, allowing for precise and tailored cancer treatment while minimizing harm to healthy tissues to enhance treatment results and patient care. The main radio theranostics radioisotopes are technetium-99, gallium-68, iodine-131, iodine-123, fludeoxyglucose-18F, yttrium-90, lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. Technetium (Tc) is a silver-gray radioactive metal that exists naturally at extremely minute levels in the earth's crust but is mostly man-made and is used to scan the skeleton and heart muscle, but it is also utilized to picture the brain, thyroid, and lungs, liver, spleen, kidney, gall bladder, bone marrow, salivary and lachrymal glands, and some specialized medical research. The various approaches are targeted therapeutic and targeted diagnostic that is applied in oncology and non-oncology. The end users are hospitals and clinics, pharmaceutical and biotechnology companies, and others.

What Is The Radiotheranostics Market Growth Forecast?

The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $19.24 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to increasing approvals of radiotheranostic drugs, rising investments in precision oncology, expansion of isotope production infrastructure, growing demand for personalized cancer care, increasing integration of ai in treatment selection. Major trends in the forecast period include increasing adoption of targeted radioligand therapies, rising use of paired diagnostic and therapeutic isotopes, growing integration of precision imaging and therapy, expansion of personalized oncology applications, enhanced focus on molecular-level cancer targeting.

Global Radiotheranostics Market Segmentation

1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes 2) By Approach: Targeted Therapeutic, Targeted Diagnostic 3) By Application: Oncology, Non-Oncology 4) By End-Users: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End-Users Subsegments: 1) By Technetium-99: Technetium-99m, Technetium-99 Pertechnetate 2) By Gallium-68: Gallium-68 DOTATATE, Gallium-68 PSMA 3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment, Iodine-131 For Hyperthyroidism Treatment 4) By Iodine-123: Iodine-123 For Thyroid Scans, Iodine-123 For Cardiac Imaging 5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging, FDG For Brain Imaging 6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer, Yttrium-90 For Radioimmunotherapy 7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer, Lutetium-177 DOTATATE For Neuroendocrine Tumors 8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy, Copper-67 In Clinical Trials 9) By Copper (Cu) 64: Copper-64 For PET Imaging, Copper-64 For Radiotherapy 10) By Other Radioisotopes: Radium-223, Samarium-153, Other Emerging Radioisotopes In Theranostics

What Is The Driver Of The Radiotheranostics Market?

The increasing prevalence of cancer is expected to propel the growth of the radiotheranostics market going forward. Cancer is a condition in which some cells in the body develop uncontrollably and spread to other regions of the body. Radiotheranostics medicines are commonly employed in cancer to offer the ultimate notion of customized medicine by using paired diagnostic and therapeutic radionuclide probes for the selective and targeted detection and treatment of specific (typically cancer) cells, each of which is suited to the patient's underlying condition to enhance treatment efficiency and better clinical output. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the increasing prevalence of cancer drives the radiotheranostics industry.

Key Players In The Global Radiotheranostics Market

Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

Global Radiotheranostics Market Trends and Insights

Major companies operating in the radiotheranostics market are focusing on developing innovative products to enhance the production and availability of therapeutic radioisotopes, improve treatment precision, and meet growing demand for targeted cancer therapies. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based company that supplies and services cyclotrons predominantly used for producing medical isotopes, introduced TR-ALPHA, a dedicated cyclotron for producing alpha-emitting radioisotopes to treat cancer. Designed to meet the market need for a cost-effective cyclotron capable of producing large quantities of Astatine-211, one of the most promising alpha-emitting radioisotopes, the TR-ALPHA is smaller, more affordable, and easier to operate than previous models, making it an ideal solution for hospitals, research institutions, and organizations aiming to efficiently manufacture therapeutic alpha-emitting radioisotopes.

What Are Latest Mergers And Acquisitions In The Radiotheranostics Market?

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. With the acquisition, Ariceum aims to broaden its portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development and to extend its operations in the US. Theranostics Ltd. is a US-based radiopharmaceutical company that offers radio-theranostics.

Regional Outlook

North America was the largest region in the radiotheranostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radiotheranostics Market?

The radiotheranostics market consists of sales of iodine-125, radium-223 (223Ra), astatin-211 (211At), actinium-225 (225Ac), lead-212 (212Pb), bismuth-212 (212Bi), thorium-227, strontium-89 (89Sr), rhenium-188 (188Re), and samarium-153 (153Sm). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Radiotheranostics Market Report 2026?

The radiotheranostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radiotheranostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.